Skip to content

Comparison of the Effects of Low-Concentration, Small-Volume Ropivacaine Brachial Plexus Upper Trunk Block Combined with Remifentanil General Anesthesia versus Sufentanil General Anesthesia in Shoulder Arthroscopic Surgery: A Randomized Controlled Equivalence Trial

Comparison of the Effects of Low-Concentration, Small-Volume Ropivacaine Brachial Plexus Upper Trunk Block Combined with Remifentanil General Anesthesia versus Sufentanil General Anesthesia in Shoulder Arthroscopic Surgery: A Randomized Controlled Equivalence Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500110372
Enrollment
Unknown
Registered
2025-10-13
Start date
2025-10-14
Completion date
Unknown
Last updated
2025-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shoulder joint diseases (those requiring shoulder arthroscopic surgery)

Interventions

Experimental Group (Remifentanil combined with nerve block group):Remifentanil combined with nerve block group: General anesthesia with remifentanil combined with upper trunk brachial plexus block (0.
Control group(Sufentanil group):None

Sponsors

Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age: 18-65 years old. 2.ASA classification: Grades I-III. 3. Type of surgery: Elective arthroscopic shoulder surgery is scheduled. 4. Informed consent: Voluntarily participate in the research and sign the informed consent form. 5. Language proficiency: Be capable of understanding and completing pain assessment scores (NRS scores) and related questionnaires. 6.BMI: 18.5-30 kg/m ^2(Avoid the influence of obesity or low weight)

Exclusion criteria

Exclusion criteria: 1.Allergic to local anesthetics 2.Contraindications for brachial plexus block (such as infection at the puncture site, coagulation disorders) 3.Uncontrolled hypertension (>180/110 mmHg) 4.Severe cardiovascular and pulmonary diseases (NYHA Class III-IV heart failure, COPD GOLD 3-4 grade) 5.Chronic pain treated with long-term use of opioid drugs 6.Severe liver and kidney dysfunction (Child-Pugh C grade or eGFR < 30 mL/min) 7.History of peripheral nerve disease or brachial plexus nerve injury 8.Cognitive impairment (inability to cooperate with pain assessment) 9.History of alcohol abuse or drug addiction 10.Pregnant or lactating women

Design outcomes

Primary

MeasureTime frame
The patient's resting pain score (NRS score) 5 minutes after awakening and extubation;

Secondary

MeasureTime frame
The amount of opioid drugs used during the operation;Postoperative remedial analgesic dosage;Awakening time;Incidence of adverse reactions;The time of the first intestinal exhaust after surgery;Pulmonary ventilation function;

Countries

China

Contacts

Public ContactYulin Wang

Qilu Hospital (Qingdao), Cheeloo College of Medicine, Shandong University

94333882@qq.com+86 532 6685 0626

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026